Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 464

The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.

Randomized Trial of Hypofractionated External-Beam Radiotherapy for Prostate Cancer

Open access
Pollack, Alan, Walker, Gail, Horwitz, Eric M., Price, Robert, Feigenberg, Steven, Konski, Andre A., Stoyanova, Radka, Movsas, Benjamin, Greenberg, Richard E., Uzzo, Robert G., Ma, Charlie, Buyyounouski, Mark K.·2013·Journal of Clinical Oncology

Abstract

Purpose: To determine if escalated radiation dose using hypofractionation significantly reduces biochemical and/or clinical disease failure (BCDF) in men treated primarily for prostate cancer. Patients and Methods: Between June 2002 and May 2006, men with favorable- to high-risk prostate cancer were randomly allocated to receive 76 Gy in 38 fractions at 2.0 Gy per fraction (conventional fractionation intensity-modulated radiation therapy [CIMRT]) versus 70.2 Gy in 26 fractions at 2.7 Gy per fraction (hypofractionated IMRT [HIMRT]); the latter was estimated to be equivalent to 84.4 Gy in 2.0 Gy fractions. High-risk patients received long-term androgen deprivation therapy (ADT), and some intermediate-risk patients received short-term ADT. The primary end point was the cumulative incidence of BCDF. Secondarily, toxicity was assessed. Results: There were 303 assessable patients with a median follow-up of 68.4 months. No significant differences were seen between the treatment arms in terms of the distribution of patients by clinicopathologic or treatment-related (ADT use and length) factors. The 5-year rates of BCDF were 21.4% (95% CI, 14.8% to 28.7%) for CIMRT and 23.3% (95% CI, 16.4% to 31.0%) for HIMRT (P = .745). There were no statistically significant differences in late toxicity between the arms; however, in subgroup analysis, patients with compromised urinary function before enrollment had significantly worse urinary function after HIMRT. Conclusion: The hypofractionation regimen did not result in a significant reduction in BCDF; however, it is delivered in 2.5 fewer weeks. Men with compromised urinary function before treatment may not be ideal candidates for this approach.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2013.51.1972

Cites

17 of 17 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 17 references

Cited by

See all 464

Metadata

Authors
Pollack, A., Walker, G., Horwitz, E. M., Price, R., Feigenberg, S., Konski, A. A., Stoyanova, R., Movsas, B., Greenberg, R. E., Uzzo, R. G., Ma, C., & Buyyounouski, M. K.
Venue
Journal of Clinical Oncology
Published
2013-11-01
Volume
31
Issue
31
Pages
3860-3868
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2111180711
Cited by
464
References
17
FWCI
36.78
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Randomized Trial of Hypofractionated External-Beam Radiotherapy for Prostate Cancer. https://app.cochat.ai/papers/10.1200/jco.2013.51.1972
The paper
Pollack, A., Walker, G., Horwitz, E. M., Price, R., Feigenberg, S., Konski, A. A., Stoyanova, R., Movsas, B., Greenberg, R. E., Uzzo, R. G., Ma, C., & Buyyounouski, M. K. (2013). Randomized Trial of Hypofractionated External-Beam Radiotherapy for Prostate Cancer. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2013.51.1972

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.